Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Latest, Q2 2026
108
Period ended Jun 30, 2026
Change on a year earlier
+14.9%
94 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
41
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Allowance for Doubtful Accounts ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 108 | +14.9% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 103 | +10.8% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 97 | +9.0% | Form 10-Q (filed 2026-08-07) ↗ |
| Q3 2025 | Sep 30, 2025 | 93 | +17.7% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 94 | +14.6% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 93 | +16.3% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 89 | +1.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 79 | -7.1% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 82 | -4.7% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 80 | +5.3% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 88 | +22.2% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2023 | Sep 30, 2023 | 85 | +10.4% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 86 | +4.9% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 76 | -20.0% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 72 | +16.1% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 77 | +11.6% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 82 | +13.9% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 95 | +21.8% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 62 | -7.5% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 69 | -22.5% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 72 | -20.0% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2021 | Mar 31, 2021 | 78 | -12.4% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 67 | -22.1% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 89 | -23.3% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 90 | -26.2% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 89 | -23.3% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 86 | -27.7% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 116 | -49.3% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 122 | -41.9% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 116 | -43.4% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 119 | -25.2% | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | 229 | +3.2% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 210 | +5.0% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 205 | +5.1% | Form 10-Q (filed 2018-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 159 | -18.5% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 222 | +28.3% | SEC Filing ↗ |
| Q2 2017 | Jun 30, 2017 | 200 | +19.8% | SEC Filing ↗ |
| Q1 2017 | Mar 31, 2017 | 195 | +4.8% | SEC Filing ↗ |
| Q4 2016 | Dec 31, 2016 | 195 | – | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 173 | – | SEC Filing ↗ |
| Q2 2016 | Jun 30, 2016 | 167 | – | SEC Filing ↗ |
| Q1 2016 | Mar 31, 2016 | 186 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Merck Allowance for Doubtful Accounts ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_bal_ar_allow
See every metric in the Merck KPI table. Data updated Oct 26, 2026.